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Abstract: The aim of this study was to
determine whether isradipine affects
microalbuminuria and other biochemical
parameters related to glucose and lipid
metabolisms. 18 subjects, 40 to 73 years of
age, with NIDDM for 0 to 21 years, blood
pressure≤140/90 mmHg in the absence of
antihypertensive treatment, and persistent
urinary albumin excretion rate (UAER) 30 to
300 mg/day, received sustained-release
(SRO) formulation isradipine at dosages of 5
mg once daily for 3 months. The effects of
isradipine on microalbuminuria, fasting
plasma glucose, plasma lipids, plasma
creatinin, uric acid, C-peptide, insulin, HbA ,
1c
fructosamine, systolic and diastolic blood

Department of 1 Internal Medicine,
2
Biochemistry, Medical Faculty of Harran
University, Şanlıurfa-Turkey

Introduction
Nephropathy is a major complication in insulindependent diabetes mellitus (IDDM) (1). In IDDM, the
presence of microalbuminuria reliably predicts the
development of diabetic nephropathy, and clinical
nephropathy is associated with a higher mortality rate (25). Although only a few studies have addressed this topic
in NIDDM, the prevalence of microalbuminuria seems to
be at least as high as in IDDM and predicts the
development of more severe proteinuria and early death
(6-11). Furthermore, a relationship between
microalbuminuria and cardiovascular diseases has been
reported in both nondiabetic and diabetic patients, and it
has been considered to be the most reliable predictor of
early mortality (12-15).
Many studies have indicated that ACE-inhibitors
decrease microalbuminuria and retard the progression of
renal disease in both hypertensive and normotensive
diabetic patients (16-23). But these results are
controversial with regard to calcium antagonists (16, 19,
24), and to our knowledge, no data are available about
the effect of isradipine, a new antihypertensive

pressure and heart rate were assayed. After
3 months of isradipine treatment, UAER fell
from 72.5±40.2 to 52.9±39.5 mg/24 h
(p<0.01). Diastolic blood pressure decreased
from 85.8±4.9 to 81.9±3.0 mmHg
(p<0.05). Other parameters were not
significantly influenced by isradipine
treatment. After 3 months of therapy,
isradipine regressed diabetic nephropathy in
normotensive NIDDM patients. No serious
clinical or metabolic side effects were
observed.
Key Words: İsradipine, microalbuminuria,
diabetic nephropathy, antihypertensive
treatment.

dihydropyridine calcium antagonist, on microalbuminuria
in normotensive NIDDM patients. Therefore, we
investigated
whether
isradipine
decreases
microalbuminuria.
Materials and Methods
The study population consisted of 18 normotensive
patients (BP ≤ 140/90 mmHg) with NIDDM, all of whom
had a UAER 30-300 mg/24 h. The subjects were in good
general health, were physically active, had no other
significant disease, were not pregnant were taking no
drugs known to affect blood pressure, carbohydrate or
lipid metabolism. The baseline characteristics of these
individuals are shown in Table 1. All subjects had been
followed up for treatment of their diabetes in the
Endocrinology polyclinic of the Research Hospital of
Harran University.
Weight and height were measured with the patients
wearing light clothing and no shoes. Body mass index
(BMI) was calculated as weight in kilograms divided by
height in meters squared (kg/m2 ). Blood pressure (BP)
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was measured in both supine and upright positions with
a mercury sphygmomanometer after 10 min rest by one
observer. Two BP measurements wereade (interval 1.5
min), and the mean calculated. A subject was excluded if
systolic blood pressure (sBP) was > 140 mmHg, diastolic
blood pressure (dBP) was > 90 mmHg, or if the subject
was receiving drug treatment for hypertension. Smoking
was defined as whether the subject was a current smoker.
Blood samples were taken between 08:00 and 09:30
after a 12-h fast. Plasma glucose, fructosamine,
Table 1.

Baseline characteristics of the study population

Variable

Range

n

18

Sex (M/F)

11/7

Age (years)

52±11

40-73

2
BMI (kg/m )

27.2±4.3

19.8-35.5

Diabetes duration (years)

5±7

0*-21

sBP (mmHg)

127±12

110±140

dBP (mmHg)

86±5

80-90

Smokers n (%)

7 (39)

Data are means±SD. *Diabetes duration <6 monnths

Variable

cholesterol, triglyceride and serum high-density
lipoprotein (HDL) cholesterol concentrations were
assayed by an autoanalyzer (Hitachi 911) using
commercial kits. Serum low-density lipoprotein (LDL)
cholesterol concentration was calculated with the
Friedwald equation in patients with triglyceridemia < 400
mg/dl (25). Plasma insulin level was determined from
samples stored at -20˚C by radioimmunoassay (RIA)
(DPC, Los Angeles, USA). Plasma C-peptide level was
determined by luminoimmunoassay (LIA) (Immulyte
hormone analyzer). HbA1c level was determined with the
microcolumn method (Biosystems, Barcelona, Spain) and
quantitative colorimetric determination (Stanbio, San
Antonio, Texas).
Urinary albumin concentration was determined as the
mean of two 24-h urine samples collected at home during
normal activity in monthly separate determinations.
Urinary albumin was measured from samples stored at
-20˚C by a commercial immunoturbidimetry assay (Orion,
Espoo, Finland). Sediment in fresh urine was assayed in
each sample and was normal in all cases.
Data analyses were performed with the SPSS ƒor
Windows 5.1 program. The results were expressed as
means±SD. The differences between before and after
treatment concerning the continuous variables were

Before treatment

After treatment

p value

UAE (mg/24h)

72.5±40.2

52.9±39.5

<0.01

FPG (mg/dl)

174.7±75.8

177.1±44.6

NS

Urea (mg/dl)

35.3±10.4

35.8±8.3

NS

Creatinin (mg/dl)

0.85±0.15

0.9±0.13

NS

Uric acid (mg/dl)

4.4±1.2

4.5±1.0

NS

Total Cholesterol (mg/dl)

236.3±33.3

232.2±31.8

NS

HDL cholesterol (mg/dl)

44.1±6.5

42.6±7.5

NS

LDL cholesterol (mg/dl)

145.3±31.0

147.5±29.8

NS

Total triglyceride (mg/dl)

224.7±98.4

218±130.3

NS

Fructosamine (mmol/L)

3.8±0.6

3.7±0.6

NS

HbA1 (%)

8.7±1.2

8.5±1.4

NS

C-peptide (ng/ml)

2.9±1.5

2.6±2.1

NS

Insulin (µU/ml)

9.8±5.8

10.2±7.1

NS

sBP (mmHg)

127±12

125±10

NS

dBP (mmHg)

86±5

82±3

<0.05

Heart rate (b/min)

89±11

93±13

NS

Data are means±SD. NS means Not Significant (statistically)
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Table 2.

Biochemical and clinical parameters
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Table 3.

Spearman correlation coefficients of UAER

n

r

P value

HbA1

18

0.57

0.01

Fructosamine

18

0.45

0.05

Total Cholesterol

18

0.45

0.05

Parameters

n= number of subjects, r= Sperman correlation coefficient

analyzed using the Wilcoxon test. Correlations between
variables were tested with the Sperman correlation
coefficient. P values < 0.05 were considered to be
statistically significant, but P values <0.10 are also
shown.
Results
There were 18 patients in this study. The base line
characteristics of the patients are shown in Table 1. When
the 18 patients were grouped according to BMI, 1 patient
was lean (<20 kg/m2 ), 5 were normal (20-24.9kg/m2 ), 8
were overweight (25-30kg/m2 ), 4 were obese
(>30kg/m2 ). 3 patients were only put on diets, 11 had
oral hypoglycemic treatment, and 4 had insulin
treatment. After 3 months of isradipin treatment, UAER
decreased from 72.5±40.2 to 52.9±39.5 mg/24
h(p<0.01), diastolic blood pressure (as the mean of
readings in the supine and upright positions) fell from
85.8±4.9 to 81.9±3.0 mmHg (p<0.05). Other
parameters did not significantly change after the
treatment (Table 2).
UAER obtained before the treatment showed a
significant positive correlation with HbA1c, and a weak
positive correlation with total cholesterol, and
fructosamine levels (Table 3). The calcium antagonist,
isradipine, was well tolerated. Only 3 patients reported
mild, transient headaches during treatment. Orthostatic
hypotension was not observed before, during or after the
treatment.
Discussion
Our study was designed to evaluate the effects of
isradipine on some clinical and metabolic parameters
(especially on UAER). Despite isradipine being an
antihypertensive drug, it was used in normotensive
NIDDM subjects because the onset of microalbuminuria or
the elevation of BP (above 120-140/80 mmHg) are
predictive of a poor evolution and require appropriate

preventive therapeutic interventions, which include an
optimal control of hyperglycemia, dietary proteins and
salt restriction, and prescription of antihypertensive
drugs, with a particular benefit ascribed to angiotensin
converting enzyme (ACE) inhibitors (and possibly certain
calcium channel blockers) (16). Several studies have
demonstrated that antihypertensives prevent the
progression of nephropathy and also regress the
nephropathy in both IDDM and NIDDM patients (17-23,
26, 27).
Microalbuminuria is defined as urinary excretion of
albumin persistently above normal, but below the
sensitivity of conventional semiquantative test strips (28,
29). We conducted this study on patients with UAE of 30300 mg/24 h as most researchers have (30-33).
There is still controversy as to whether increased
UAER in patients with NIDDM has similar pathognomonic
relevance as in IDDM and whether antihypertensive
treatment may beneficially influence increased UAE in
patients with NIDDM to the same extent as in patients
with IDDM (34). Many studies have suggested that ACE
inhibitors may be effective in preventing the onset of
nephropathy and its treatment in hypertensive and
normotensive diabetic patients (18, 20, 23, 35).
However, few studies have assessed the effects of other
antihypertensives on UAER in diabetic patients, and the
results are controversial (36-44). Some researchers have
reported that nifedipine increased UAER in
normontensive microalbuminuric insulin-dependent
diabetic subjects, in contrast to captopril or placebo (24,
37, 38). Some of them have reported that calcium
antagonists did not change UAER (42, 44). But others
have reported beneficial nephroprotective effects of
calcium antagonists on diabetic patients (16, 19, 39-41,
43). Norgaard K et al. have suggested that isradipine did
not change UAER in hypertensive IDDM patients (45). In
contrast, Frishman WH and Guistino A et al. have
reported a favorable renal effect profile of isradipine in
essential hypertension (46, 47). In this study, isradipine
led to a decrease in UAER. This decrease was not
attributable only to its beneficial blood pressure lowering
effect because it decreased only diastolic blood pressure
and also this decrease (p<0.05) was not as significant as
the decrease in UAER (p<0.01). Similarly several
prospective studies have claimed that antihypertensives
exert nephroprotective effects beyond their BP lowering
effects (19, 20, 26).
Like previous researchers (48, 49), we observed that
isradipine did not significantly affect the mean levels of
FPG, total cholesterol, HDL cholesterol, LDL cholesterol,
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urea, cretainin, uric acid, glycosylated hemoglobin,
fructosamine, C-peptid or insulin. Therefore, such drugs
(ACE inhibitors, calcium antagonists, and α-Adrenergic
inhibitors) are called metabolic neutral drugs, and they
are referred in the treatment of diabetic patients (19,
50). However, their potential adverse effects should be
considered. Hyperkalemia is common with the use of ACE
inhibitors. Pregnancy or possible pregnancy is a
contraindication of the use of ACE inhibitors. αAdrenergic inhibitors may cause persistent orthostatic
hypotension and fluid retention in diabetic patients (50,
51). Isradipine has some adverse effects related to
vasodilatation (such as ankle edema, headaches and
dizziness) (48, 52-55). In this study, no serious clinical or
metabolic side effects were noted, except headaches in 3
patients, but they did not require discontinuation of the
treatment. Furthermore, isradipine did not cause
ortostatic hypotension.
In basal conditions, neither sBP nor dBP was
significantly correlated with UAER (r=0.36, p=0.13 and

r=-0.13, p=0.58, respectively). This finding is consistent
with previous observations (7-10, 26). These data
suggest that blood pressure NIDDM patients, unlike in
IDDM patients, does not strictly depend on the degree of
renal impairment. This assumption is confirmed by the
fact that approximately 20% of NIDDM patients are
hypertensive before diagnosis, with several other
pathogenic mechanisms playing a major role (26, 50).
However, UAER was strongly correlated with glycosylated
hemoglobin (r=0.57, p=0.01) and weakly correlated
with fructosamine and total cholesterol (r=0.45, p=0.05;
and r=0.45, p=0.05; respectively).
In conclusion, isradipine is safe and well tolerated by
normotensive microalbuminuric patients with NIDDM.
Isradipine treatment reduces urinary albumin excretion.
Although the mechanisms of the renal effects o f
isradipine have not been fully elucidated, these results
indicate the potential use of this drug in the long-term
renal protection of normotensive microalbuminuric
patients with NIDDM.
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